Kopran Limited has reported a significant 25% decline in revenue, totaling ₹11,791 crore for the second quarter of FY 2025-26, compared to ₹15,156 crore in the same quarter last year. This drop reflects a sharper decline from the previous quarter's revenue of ₹13,522 crore. The company attributes this downturn to a combination of factors affecting its Active Pharmaceutical Ingredients (API) and formulation sectors, amid a challenging market environment. The unaudited financial results were disclosed in an investor presentation dated November 12, 2025, and are also accessible on the company’s official website.

The company’s financial performance shows a dramatic impact on profitability, with a net loss of ₹992 crore for the quarter, contrasting starkly with a profit of ₹738 crore posted in Q2 FY 2024-25. EBITDA also plummeted to ₹296 crore, down from ₹1,474 crore year-on-year, resulting in an EBITDA margin of just 2.51%, a significant decline from 10.45% in the previous quarter. This downturn has been exacerbated by finance costs rising to ₹209 crore and substantial foreign exchange losses amounting to ₹824 crore, which have further strained the company’s financial health.

Kopran's results indicate a pressing need for strategic adjustments as the company navigates this downturn. The half-year report shows total revenue at ₹25,313 crore, reflecting ongoing operational challenges. As the company seeks to stabilize and rebound, stakeholders are advised to closely monitor its future performance and strategic initiatives aimed at recovering lost ground in the competitive pharmaceutical landscape. The ongoing shifts in the industry landscape could present both challenges and opportunities as Kopran works to restore its profitability and operational efficiency.